Physician profile
Julia Shatten
NPI 1205330784
$2,205.85
in general payments reported to CMS, 2019-2025
11 companies · $862 in 2025
The $862 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $86.62 · 2023: $766 · 2024: $491 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758 · Travel and Lodging: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.29 |
| Travel and Lodging | $360.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $974.49 | 2022-2025 | Clareon, Clareon Panoptix Pro, Unity |
| Glaukos Corporation | $389.75 | 2023-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem, Photrexa Viscous and Photrexa |
| Abbvie INC. | $346.04 | 2024-2025 | |
| Biotissue Holdings INC. | $248.15 | 2025 | |
| Dompe US, INC. | $68.05 | 2024 | Oxervate |
| Mallinckrodt Hospital Products INC. | $48.75 | 2025 | Acthar |
| Genentech USA, INC. | $34.20 | 2023 | Vabysmo |
| Lkc Technologies, INC. | $28.93 | 2025 | |
| Bausch & Lomb Americas INC. | $24.52 | 2025 | Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $23.55 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $19.42 | 2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Shatten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.